Cat. No.: HY-101566A

Elimusertib hydrochloride

(Synonyms: BAY 1895344 hydrochloride)

17 Cited Publications

Customer Review

Based on 17 publication(s) in Google Scholar

Elimusertib (BAY 1895344) hydrochloride is a potent, orally active and selective ATR inhibitor with an IC₅₀ of 7 nM. Elimusertib hydrochloride has anti-tumor activity. Elimusertib hydrochloride can be used for the research of solid tumors and lymphomas.

For research use only. We do not sell to patients.

Purity: 99.85%
Formula: C₂₀H₂₂ClN₇O
Molecular Weight:411.89

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

Elimusertib hydrochloride Chemical Structure

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
- Clinical Trial
Chemical Information
Publications (17)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

Elimusertib (BAY 1895344) hydrochloride is a potent, orally active and selective ATR inhibitor with an IC₅₀ of 7 nM. Elimusertib hydrochloride has anti-tumor activity^[1]^[2]. Elimusertib hydrochloride can be used for the research of solid tumors and lymphomas^[3].

IC₅₀ & Target^[1]

ATR

7 nM (IC₅₀)

All ATM/ATR Isoforms :

In Vitro

Elimusertib hydrochloride potently inhibits the proliferation of a broad spectrum of human tumor cell lines with a median IC₅₀ of 78 nM^[1].
Elimusertib hydrochloride potently suppresses hydroxyurea-induced H2AX phosphorylation (IC₅₀: 36 nM)^[1].
Elimusertib hydrochloride shows good selectivity against mTOR (ratio of IC₅₀ values: mTOR/ATR 61)^[3].
Elimusertib hydrochloride reveals high selectivity against other related kinases, such as DNA-PK (IC₅₀: 332 nM), ATM (IC₅₀: 1420 nM), and PI3K (IC₅₀: 3270 nM)^[3].
Elimusertib hydrochloride has potent antiproliferative activity against various cancer cell lines in vitro, 25 for example in the CRC cell lines HT-29 (IC₅₀: 160 nM) and LoVo (IC₅₀: 71 nM), and in the B-cell lymphoma cell line SU-DHL-8 (IC₅₀: 9 nM)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Elimusertib hydrochloride shows potent anti-tumor efficacy in monotherapy in a variety of xenograft models of ovarian and colorectal cancer, and causes complete tumor remission in mantle cell lymphoma models^[2].
Elimusertib hydrochloride (50 mg/kg; p.o.; b.i.d.; 3 days on/4 days off; for 11 days) exhibits strong antitumor efficacy in the ATM-mutated SU-DHL-8 (ATM K1964E) human GCB-DLBCL cell line derived xenograft model in mice^[3].
Elimusertib hydrochloride (20 mg/kg, and 10 mg/kg from day 14; p.o.; daily; 2 days on/5 days off; for 42 days) in combination with Carboplatin (40 mg/kg; i.p.; daily; 1 day on/6 days off) results in synergistic antitumor activity in the platinum-resistant ATM protein low expressing CR5038 human CRC PDX model in NOD/SCID mice^[3].
Elimusertib hydrochloride exhibits moderate oral bioavailability (rat 87%, dog 51%) following oral administration (rat and dog 0.6-1 mg/kg)^[3].
Elimusertib hydrochloride exhibits terminal elimination half-lives (mouse 0.17 h, rat 1.3 and, dog 1.0 h) due to plasma clearance (3.5, 1.2, and 0.79 L/h/kg respectively) following intravenous administration (mouse, rat and dog 0.3-0.5 mg/kg)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Female C.B-17 SCID mice, SU-DHL-8 GCB-DLBCL xenograft model^[3]
Dosage:

50 mg/kg
Administration:

Oral administration, b.i.d., 3 days on/4 days off, for 11 days
Result:

Inhibited tumor area.

Animal Model:

Male Wistar rats^[3]
Dosage:

0.3-0.5 mg/kg for i.v.; 0.6-1 mg/kg for oral (Pharmacokinetic Analysis)
Administration:

Intravenous injection and oral administration
Result:

Oral bioavailability (87%), T_1/2 (1.3 h).

Animal Model:

Female beagle dogs^[3]
Dosage:

0.3-0.5 mg/kg for i.v.; 0.6-1 mg/kg for oral (Pharmacokinetic Analysis)
Administration:

Intravenous injection and oral administration
Result:

Oral bioavailability (51%), T_1/2 (1.0 h).

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

Appearance Solid
Molecular Weight 411.89
Formula C₂₀H₂₂ClN₇O
Color Yellow to orange
SMILES

CN1N=CC=C1C2=C(C=CN=C3C4=CC=NN4)C3=NC(N5[C@H](C)COCC5)=C2.[H]Cl
Synonyms

BAY 1895344 hydrochloride
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture)

Publications (17)

All WBBio/Physico-chemical AssayCell Proliferation/Viability Assay

Sort by:

Journal Impact Factor

Cancer Res

Combined Inactivation of CTPS1 and ATR Is Synthetically Lethal to MYC-Overexpressing Cancer Cells. [Abstract]

2022 Mar 15;82(6):1013-1024. PMID: 35022212
Nat Commun

X-ray preactivated reversible persistent luminescence enables photodynamic immunotherapy of deep tumors. [Abstract]

2026 Mar 21. PMID: 41865031
Nat Commun

Stepwise phosphorylation and SUMOylation of PIDD1 drive PIDDosome assembly in response to DNA repair failure. [Abstract]

2024 Oct 24;15(1):9195. PMID: 39448602

Elimusertib hydrochloride purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Oct 24;15(1):9195. [Abstract]

PIDD1−/− HeLa cells transfected with indicated FLAG-PIDD1 variants with or without ATR inhibitor BAY 1895344 (BAY, 0.75 mM)were harvested at 24 h, immunoprecipitated with anti-PIDD1 pT788 antibody, and analyzed by western blot.
Exp Mol Med

Inhibition of GSK3β is synthetic lethal with FHIT loss in lung cancer by blocking homologous recombination repair. [Abstract]

2025 Feb;57(1):167-183. PMID: 39762409

Elimusertib hydrochloride purchased from MedChemExpress. Usage Cited in: Exp Mol Med. 2025 Feb;57(1):167-183. [Abstract]

Effects of Elimusertib on p-BRCA1 (s1423), BRCA1, and RAD51 protein levels. The cells were treated with 0.2 μM Elimusertib for 24 h, and Western blotting was used to detect protein expression. GAPDH was used as the internal control. All FHIT-deficient cells are marked in red.
Cell Rep Med

Organoid morphology-guided classification for oral cancer reveals prognosis. [Abstract]

2025 May 6:102129. PMID: 40359934

Elimusertib hydrochloride purchased from MedChemExpress. Usage Cited in: Cell Rep Med. 2025 May 6:102129. [Abstract]

Comparison of synergy scores for cisplatin by target drug. The Bliss score was calculated using SynergyFinder to evaluate the synergistic effects of BAY1895344 (0.01 μM; 5 days), AZD7762, EPZ015666, or everolimus in combination with cisplatin across 27 OSCC organoids, comprising 10 normal-like, 8 dense, and 9 grape-like subtypes.
Sci Adv

PARP4 ADP-ribosylates PIDD1 to complete a phospho/SUMO/PAR-ylation cascade that orchestrates PIDDosome assembly. [Abstract]

2026 May;12(18):eadz9284. PMID: 42054439
Cancer Lett

2026 Feb 4;642:218300.
Cancer Lett

Targeting ATR signaling in sarcoma with homologous recombination deficiency. [Abstract]

2026 Apr 1:642:218300. PMID: 41651400
J Med Chem

Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500). [Abstract]

2024 Feb 22;67(4):2349-2368. PMID: 38299539
Biochem Pharmacol

Cytarabine-induced destabilization of MCL1 mRNA and protein triggers apoptosis in leukemia cells. [Abstract]

2023 May:211:115494. PMID: 36924905

Elimusertib hydrochloride purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2023 May:211:115494. [Abstract]

Elimusertib (10 μM; 1 h) pretreatment inhibits Ara-C-induced p38 MAPK phosphorylation but does not inhibit AKT dephosphorylation.
RSC Adv

Injectable thermosensitive hydrogel co-loading with ATRi and doxorubicin for the treatment of triple-negative breast cancer. [Abstract]

2025 Jun 16;15(26):20385-20396. PMID: 40530304
EMBO Rep

Tumor acidosis-induced DNA damage response and tetraploidy enhance sensitivity to ATM and ATR inhibitors. [Abstract]

2024 Mar;25(3):1469-1489. PMID: 38366255

Elimusertib hydrochloride purchased from MedChemExpress. Usage Cited in: EMBO Rep. 2024 Mar;25(3):1469-1489. [Abstract]

Cell viability assays in HCT116 and HT-29 cancer cells cultured at pH 7.4 or 6.5, and treated with the indicated doses of ATRi Elimusertib (0.03-1 μM) for 72 h.
Mol Cell Biol

Kinase Inhibitor-Induced Cell-Type Specific Vacuole Formation in the Absence of Canonical ATG5-Dependent Autophagy Initiation Pathway. [Abstract]

2025;45(3):99-115. PMID: 39895059
bioRxiv

Glutamine antagonism suppresses tumor growth in adrenocortical carcinoma through inhibition of de novo nucleotide biosynthesis. [Abstract]

2025 Sep 29:2025.09.28.674326. PMID: 41256360
Research Square Preprint

2023 Nov 20.
Research Square Preprint

2023 Jun 9.
Research Square Preprint

2023 May 17.

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (121.39 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 50 mg/mL (121.39 mM; Need ultrasonic)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.4278 mL

12.1392 mL

24.2783 mL

5 mM

0.4856 mL

2.4278 mL

4.8557 mL

10 mM

0.2428 mL

1.2139 mL

2.4278 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (sealed storage, away from moisture). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (5.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (5.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (5.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (242.78 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (283 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Ulrich T. Luecking, et al. Abstract 983: Identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement.

[2]. Antje Margret Wengner, et al. Abstract 836: ATR inhibitor BAY 1895344 shows potent anti-tumor efficacy in monotherapy and strong combination potential with the targeted alpha therapy Radium-223 dichloride in preclinical tumor models. Cancer Research. July 2017 Volume 77, Issue 13 Supplement

[3]. Ulrich Lücking, et al. Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models. J Med Chem. 2020 Jul 9;63(13):7293-7325. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO / H₂O	1 mM	2.4278 mL	12.1392 mL	24.2783 mL	60.6958 mL
	5 mM	0.4856 mL	2.4278 mL	4.8557 mL	12.1392 mL
	10 mM	0.2428 mL	1.2139 mL	2.4278 mL	6.0696 mL
	15 mM	0.1619 mL	0.8093 mL	1.6186 mL	4.0464 mL
	20 mM	0.1214 mL	0.6070 mL	1.2139 mL	3.0348 mL
	25 mM	0.0971 mL	0.4856 mL	0.9711 mL	2.4278 mL
	30 mM	0.0809 mL	0.4046 mL	0.8093 mL	2.0232 mL
	40 mM	0.0607 mL	0.3035 mL	0.6070 mL	1.5174 mL
	50 mM	0.0486 mL	0.2428 mL	0.4856 mL	1.2139 mL
	60 mM	0.0405 mL	0.2023 mL	0.4046 mL	1.0116 mL
	80 mM	0.0303 mL	0.1517 mL	0.3035 mL	0.7587 mL
	100 mM	0.0243 mL	0.1214 mL	0.2428 mL	0.6070 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

Elimusertib hydrochloride

17 Cited Publications

100 mg Get Quote

Subscribe to the

MedChemExpress

Newsletter

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Elimusertib hydrochloride

Cell Cycle/DNA Damage Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Anti-Aging Compound Library

Drug Repurposing Compound Library

Oxygen Sensing Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Orally Active Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Glucose Metabolism Compound Library

Targeted Diversity Library

Anti-Prostate Cancer Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Highly Selective Inhibitors Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Protein Kinase Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

High-Efficiency Gene Editing Compound Library

Publications Citing Use of MedChemExpress (MCE) Elimusertib hydrochloride

All ATM/ATR Isoforms

Biological Activity

Chemical Information

Publications (17)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Elimusertib hydrochloride Related Classifications

HY-101566A Related Classifications